(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-17-(2-quinolin-2-ylsulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one | 1166866-58-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-17-(2-quinolin-2-ylsulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
• CAS: 1166866-58-5
• 化学式: C₃₀H₃₅NO₄S
• 分子量: 505.678
• InChiKey: YAMZICGYSATAPJ-QYPWACJRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  36
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  6

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  氢化可的松	HYDROCORTISONE	50-23-7	C21H30O5	362.466
  11beta,17,21-三羟基孕甾-4-烯-3,20-二酮 21-甲烷磺酸酯	Cortisol 21-mesylate	6677-96-9	C22H32O7S	440.558

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	[(8S,9S,10R,11S,13S,14S,17R)-11-hydroxy-10,13-dimethyl-3-oxo-17-(2-quinolin-2-ylsulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] furan-2-carboxylate	1166866-33-6	C35H37NO6S	599.748

反应信息

• 作为反应物：
  描述：

  呋喃甲酰氯 、 (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-17-(2-quinolin-2-ylsulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one 在 4-二甲氨基吡啶 作用下， 以 二氯甲烷 为溶剂， 生成 [(8S,9S,10R,11S,13S,14S,17R)-11-hydroxy-10,13-dimethyl-3-oxo-17-(2-quinolin-2-ylsulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] furan-2-carboxylate
  参考文献：
  名称：

  Steroidal C-21 mercapto derivatives as dissociated steroids: Discovery of an inhaled dissociated steroid

  摘要：

  A series of C-21 mercapto derivatives of hydrocortisone have been synthesized and evaluated in cell based transrepression and transactivation assays. The benzothiazole derivative, compound 6 not only showed a dissociated profile in vitro functional assays but also a pharmacological profile in a Brown-Norway rat therapeutic index model of asthma that dissociated side effects (thymolysis) while maintaining efficacy against pulmonary inflammation and lung function. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.108
• 作为产物：
  描述：

  氢化可的松 在 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 生成 (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-17-(2-quinolin-2-ylsulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
  参考文献：
  名称：

  Steroidal C-21 mercapto derivatives as dissociated steroids: Discovery of an inhaled dissociated steroid

  摘要：

  A series of C-21 mercapto derivatives of hydrocortisone have been synthesized and evaluated in cell based transrepression and transactivation assays. The benzothiazole derivative, compound 6 not only showed a dissociated profile in vitro functional assays but also a pharmacological profile in a Brown-Norway rat therapeutic index model of asthma that dissociated side effects (thymolysis) while maintaining efficacy against pulmonary inflammation and lung function. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.108

文献信息

• [EN] C20-C21 SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR DE GLUCOCORTICOÏDE SUBSTITUÉS EN C20-C21
  申请人：SCHERING CORP

  公开号：WO2009085879A2

  公开（公告）日：2009-07-09

  The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, or isomers of said compounds), having general structure (I); wherein L, R1, R2, R3, R4, R5, and R6 are selected independently of each other and as defined herein. The present invention also provides compounds (and salts, solvates, esters, prodrugs, tautomers, and isomers) of Formulas II, III, IV, V, and Vl, as defined herein. Also provided are pharmaceutical compositions, methods of preparing, and methods of using such compounds in the treatment and prophylaxis of a wide range of immune, autoimmune, and inflammatory diseases and conditions.

  本发明提供了具有一般结构（I）的化合物，以及该化合物的药用盐、溶剂合物、酯、前药、互变体或异构体（包括L、R1、R2、R3、R4、R5和R6在内独立选择的定义）。本发明还提供了根据本文所定义的化合物（和盐、溶剂合物、酯、前药、互变体和异构体）的II、III、IV、V和VI式化合物。还提供了药物组合物、制备方法以及利用这些化合物在治疗和预防各种免疫、自身免疫和炎症性疾病和症状中的方法。